GLP-1受容体作動薬の世界市場レポート 2024年

GLP-1受容体作動薬の市場規模は近年着実に成長しています。2023年の131億米ドルから2024年には137億4,000万米ドルへと、CAGR4.9％で拡大します。過去数年間に見られた成長は、糖尿病有病率の増加、治療法の臨床的有効性、患者の意識と受容の高まり、世界の健康イニシアチブ、注射療法に対する患者の嗜好などに起因しています。

GLP-1受容体作動薬市場の成長は、糖尿病有病率の増加によって促進されると予測されます。糖尿病は、膵臓によるインスリン分泌不全や、分泌されたインスリンが体内で効果的に使用されないことに起因する慢性疾患です。高血糖は、糖尿病として知られるこの代謝障害の特徴的な症状です。GLP-1受容体作動薬は、インスリンの産生を刺激することによって血糖値を下げるという、糖尿病管理において重要な役割を果たしています。国際糖尿病連合は2021年12月、全世界で約5億3,700万人の成人が糖尿病を患っていると報告し、この数は2030年までに6億4,300万人に増加すると予想されています。したがって、糖尿病の有病率の上昇は、GLP-1受容体作動薬市場の成長を促進する重要な要因です。

GLP-1受容体作動薬市場の成長は、肥満症例の増加によっても後押しされると予想されます。肥満は、体脂肪の過剰蓄積を特徴とする病状であり、さまざまな健康リスクと関連しています。GLP-1受容体作動薬は、食欲と血糖値を調節する天然に存在するホルモンGLP-1の作用を模倣することにより、肥満治療に有効であることを示しています。世界保健機関（WHO）の2022年3月の報告書によると、世界全体で10億人以上が肥満の影響を受けており、その内訳は成人6億5,000万人、青年3億4,000万人、小児3,900万人で、この数は増加の一途をたどっています。約1億6,700万人が過体重または肥満のために健康を損なう可能性があると推定されています。したがって、肥満の有病率の増加がGLP-1受容体作動薬市場の成長に寄与しています。

2023年のGLP-1受容体作動薬市場で最大の地域は北米です。アジア太平洋は、GLP-1受容体作動薬市場レポートにおいて予測期間中に最も急成長する地域となる見込みです。GLP-1受容体作動薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 GLP-1受容体作動薬市場の特徴

第3章 GLP-1受容体作動薬の市場動向と戦略

第4章 GLP-1受容体作動薬市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界のGLP-1受容体作動薬市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 GLP-1受容体作動薬市場セグメンテーション

• 世界のGLP-1受容体作動薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• エクセナチド
• リラグルチド
• デュラグルチド
• リキシセナチド
• その他の薬物
• 世界のGLP-1受容体作動薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 非経口
• 経口
• 世界のGLP-1受容体作動薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 外科クリニック
• その他

第7章 GLP-1受容体作動薬市場の地域および国分析

• 世界のGLP-1受容体作動薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のGLP-1受容体作動薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋のGLP-1受容体作動薬市場

第9章 中国のGLP-1受容体作動薬市場

第10章 インドのGLP-1受容体作動薬市場

第11章 日本のGLP-1受容体作動薬市場

第12章 オーストラリアのGLP-1受容体作動薬市場

第13章 インドネシアのGLP-1受容体作動薬市場

第14章 韓国のGLP-1受容体作動薬市場

第15章 西欧のGLP-1受容体作動薬市場

第16章 英国のGLP-1受容体作動薬市場

第17章 ドイツのGLP-1受容体作動薬市場

第18章 フランスのGLP-1受容体作動薬市場

第19章 イタリアのGLP-1受容体作動薬市場

第20章 スペインのGLP-1受容体作動薬市場

第21章 東欧のGLP-1受容体作動薬市場

第22章 ロシアのGLP-1受容体作動薬市場

第23章 北米のGLP-1受容体作動薬市場

第24章 米国のGLP-1受容体作動薬市場

第25章 カナダのGLP-1受容体作動薬市場

第26章 南米GLP-1受容体作動薬市場

第27章 ブラジルのGLP-1受容体作動薬市場

第28章 中東のGLP-1受容体作動薬市場

第29章 アフリカのGLP-1受容体作動薬市場

第30章 GLP-1受容体作動薬市場の競合情勢と企業プロファイル

• GLP-1受容体作動薬市場の競合情勢
• GLP-1受容体作動薬市場の企業プロファイル
  • Novo Nordisk A/S
  • Sanofi SA
  • Eli Lilly and Company
  • AstraZeneca Inc.
  • Boehringer Ingelheim International GmbH

第31章 世界のGLP-1受容体作動薬市場の競合ベンチマーキング

第32章 世界GLP-1受容体作動薬市場競争ダッシュボード

第33章 GLP-1受容体作動薬市場における主要な合併と買収

第34章 GLP-1受容体作動薬市場の将来展望と可能性分析

第35章 付録

“GLP-1 Receptor Agonist Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glp-1 receptor agonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glp-1 receptor agonist? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The glp-1 receptor agonist market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Class: Exenatide; Liraglutide; Dulaglutide; Lixisenatide; Other Drugs
• 2) By Route Of Administration: Parenteral; Oral
• 3) By End Users: Hospitals; Surgical Clinics; Other Users
• Companies Mentioned: Novo Nordisk A/S; Sanofi SA; Eli Lilly and Company; AstraZeneca Inc.; Boehringer Ingelheim International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

A GLP-1 receptor agonist is a type of medication designed to stimulate insulin release when blood glucose levels are elevated and to inhibit glucagon secretion in the presence of low blood glucose conditions. These medications are primarily employed in the treatment of type 2 diabetes mellitus.

The main drug class of GLP-1 receptor agonists includes liraglutide, dulaglutide, lixisenatide, and others. Liraglutide, for instance, is a GLP-1 receptor agonist that facilitates the release of an appropriate amount of insulin from the pancreas in response to elevated blood sugar levels. These medications are administered through parenteral and oral routes, commonly utilized in settings such as hospitals, surgical clinics, and other medical facilities.

The GLP-1 receptor agonist market research report is one of a series of new reports from The Business Research Company that provides GLP-1 receptor agonist market statistics, including GLP-1 receptor agonist industry global market size, regional shares, competitors with GLP-1 receptor agonist market share, detailed GLP-1 receptor agonist market segments, market trends, and opportunities, and any further data you may need to thrive in the GLP-1 receptor agonist industry. This GLP-1 receptor agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The glp-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.1 billion in 2023 to $13.74 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth observed in the historical period can be attributed to the increasing prevalence of diabetes, the clinical efficacy of treatments, growing patient awareness and acceptance, global health initiatives, and the preference among patients for injectable therapies.

The glp-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $16.82 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period can be attributed to the increasing emphasis on lifestyle management, the adoption of personalized medicine approaches, the expansion of indications, the development of next-generation products, and integration into combination therapies. Major trends expected in the forecast period include the introduction of oral formulations, a focus on combination therapies, strategic partnerships and collaborations, considerations for reimbursement policies and access, and the adoption of patient-centric approaches.

The growth of the GLP-1 receptor agonist market is anticipated to be fueled by the increasing prevalence of diabetes. Diabetes is a chronic condition resulting from inadequate insulin production by the pancreas or ineffective use of the produced insulin by the body. High blood sugar is a characteristic symptom of this metabolic disorder known as diabetes mellitus. GLP-1 receptor agonists play a crucial role in diabetes management by stimulating the production of insulin, thereby lowering blood sugar levels. The International Diabetes Federation reported in December 2021 that approximately 537 million adults globally are living with diabetes, and this number is expected to rise to 643 million by 2030. Hence, the escalating prevalence of diabetes is a significant factor driving the growth of the GLP-1 receptor agonist market.

The growth of the GLP-1 receptor agonist market is also expected to be boosted by the increasing cases of obesity. Obesity, a medical condition characterized by excessive body fat accumulation, is associated with various health risks. GLP-1 receptor agonists have shown effectiveness in treating obesity by mimicking the effects of the naturally occurring hormone GLP-1, which regulates appetite and blood sugar levels. According to the World Health Organization's March 2022 report, over 1 billion individuals globally are affected by obesity, including 650 million adults, 340 million adolescents, and 39 million children, with this number continuing to rise. It is estimated that around 167 million people may experience compromised health due to being overweight or obese. Therefore, the increasing prevalence of obesity is contributing to the growth of the GLP-1 receptor agonist market.

A key trend gaining momentum in the GLP-1 receptor agonist market is product innovation, with major companies focusing on developing innovative solutions to strengthen their market position. For instance, in May 2022, Eli Lilly and Company launched Mounjaro, an FDA-approved GIP and GLP-1 receptor agonist designed using a single molecule to activate the body's receptors for incretin hormones. This product is available as a pen auto-injector with a pre-attached, hidden needle, providing convenience for patients.

Major companies in the GLP-1 receptor agonist market are concentrating on developing sustained-release GLP-1 receptor agonists to gain a competitive edge. Sustained-release GLP-1 receptor agonists slowly release the medication into the bloodstream, allowing for longer-lasting effects and less frequent injections compared to traditional GLP-1 receptor agonists. Mitsubishi Tanabe Pharma Corporation launched Mounjaro 2.5 mg or 5 mg Ateos in April 2023, which is the world's first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes.

In February 2022, Sanofi S.A. strengthened its position in the market by acquiring Amunix Pharmaceuticals Inc., a US-based immuno-oncology company developing GLP-1 receptor agonists and transformative therapies for cancer. The acquisition is expected to provide Sanofi access to various products and technologies, including next-generation conditionally activated biologics.

Major companies operating in the glp-1 receptor agonist market report are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., 9 Meters Biopharma Inc., Intarcia Therapeutics Inc., Amylin Pharmaceuticals Inc., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., CymaBay Therapeutics Inc., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., Genentech Inc., GlaxoSmithKline plc, HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Kowa Company Ltd., LG Chem Ltd., Ligand Pharmaceuticals Incorporated, Merck & Co. Inc., Novartis AG .

North America was the largest region in the GLP-1 receptor agonist market in 2023. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glp-1 receptor agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The GLP-1 receptor agonist market consists of sales of dulaglutide, bydureon b-cise, exenatide, and semaglutide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. GLP-1 Receptor Agonist Market Characteristics

3. GLP-1 Receptor Agonist Market Trends And Strategies

4. GLP-1 Receptor Agonist Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global GLP-1 Receptor Agonist Market Size and Growth

• 5.1. Global GLP-1 Receptor Agonist Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global GLP-1 Receptor Agonist Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global GLP-1 Receptor Agonist Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. GLP-1 Receptor Agonist Market Segmentation

• 6.1. Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Exenatide
• Liraglutide
• Dulaglutide
• Lixisenatide
• Other Drugs
• 6.2. Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Parenteral
• Oral
• 6.3. Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Surgical Clinics
• Other Users

7. GLP-1 Receptor Agonist Market Regional And Country Analysis

• 7.1. Global GLP-1 Receptor Agonist Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global GLP-1 Receptor Agonist Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific GLP-1 Receptor Agonist Market

• 8.1. Asia-Pacific GLP-1 Receptor Agonist Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China GLP-1 Receptor Agonist Market

• 9.1. China GLP-1 Receptor Agonist Market Overview
• 9.2. China GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India GLP-1 Receptor Agonist Market

• 10.1. India GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan GLP-1 Receptor Agonist Market

• 11.1. Japan GLP-1 Receptor Agonist Market Overview
• 11.2. Japan GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia GLP-1 Receptor Agonist Market

• 12.1. Australia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia GLP-1 Receptor Agonist Market

• 13.1. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea GLP-1 Receptor Agonist Market

• 14.1. South Korea GLP-1 Receptor Agonist Market Overview
• 14.2. South Korea GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe GLP-1 Receptor Agonist Market

• 15.1. Western Europe GLP-1 Receptor Agonist Market Overview
• 15.2. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK GLP-1 Receptor Agonist Market

• 16.1. UK GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany GLP-1 Receptor Agonist Market

• 17.1. Germany GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France GLP-1 Receptor Agonist Market

• 18.1. France GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy GLP-1 Receptor Agonist Market

• 19.1. Italy GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain GLP-1 Receptor Agonist Market

• 20.1. Spain GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe GLP-1 Receptor Agonist Market

• 21.1. Eastern Europe GLP-1 Receptor Agonist Market Overview
• 21.2. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia GLP-1 Receptor Agonist Market

• 22.1. Russia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America GLP-1 Receptor Agonist Market

• 23.1. North America GLP-1 Receptor Agonist Market Overview
• 23.2. North America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA GLP-1 Receptor Agonist Market

• 24.1. USA GLP-1 Receptor Agonist Market Overview
• 24.2. USA GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada GLP-1 Receptor Agonist Market

• 25.1. Canada GLP-1 Receptor Agonist Market Overview
• 25.2. Canada GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America GLP-1 Receptor Agonist Market

• 26.1. South America GLP-1 Receptor Agonist Market Overview
• 26.2. South America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil GLP-1 Receptor Agonist Market

• 27.1. Brazil GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East GLP-1 Receptor Agonist Market

• 28.1. Middle East GLP-1 Receptor Agonist Market Overview
• 28.2. Middle East GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa GLP-1 Receptor Agonist Market

• 29.1. Africa GLP-1 Receptor Agonist Market Overview
• 29.2. Africa GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. GLP-1 Receptor Agonist Market Competitive Landscape And Company Profiles

• 30.1. GLP-1 Receptor Agonist Market Competitive Landscape
• 30.2. GLP-1 Receptor Agonist Market Company Profiles
  • 30.2.1. Novo Nordisk A/S
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Sanofi SA
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Eli Lilly and Company
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AstraZeneca Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Boehringer Ingelheim International GmbH
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global GLP-1 Receptor Agonist Market Competitive Benchmarking

32. Global GLP-1 Receptor Agonist Market Competitive Dashboard

33. Key Mergers And Acquisitions In The GLP-1 Receptor Agonist Market

34. GLP-1 Receptor Agonist Market Future Outlook and Potential Analysis

• 34.1 GLP-1 Receptor Agonist Market In 2028 - Countries Offering Most New Opportunities
• 34.2 GLP-1 Receptor Agonist Market In 2028 - Segments Offering Most New Opportunities
• 34.3 GLP-1 Receptor Agonist Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer